Medtronic (NYSE:MDT) said today that its Envision Pro continuous glucose monitoring system received CE Mark approval and will be commercialized in Europe and the Middle East this fall.
The Envision Pro CGM is designed to provide blinded glucose levels, track events and compile reports for physicians to assess therapies. The CGM collects glucose data to generate up to five diagnostic reports, including the Pattern Snapshot, which is designed to identify patterns of high and low sugar levels and their association with food, medication, exercise and sleep. It does not require finger-stick calibration and communicates wirelessly with the patient’s smartphone.
“Medtronic has a 20-year history in professional CGM as the first company to have an approved physician-use CGM system,” Medtronic VP & GM for non-intensive diabetes therapies Sheri Dodd said in prepared remarks. “The launch of the Envision Pro CGM system represents multiple important innovations as the first disposable and zero calibration CGM from Medtronic.”
“Fingersticks and A1C only show part of how a person’s sugar levels are fluctuating throughout the day,” added Antwerp University Hospital head of endocrinology-diabetology-metabolism Dr. Christophe De Block. “The Envision Pro CGM system will allow me and my patients to see the percent of time that they are in the optimal target glucose range, and when they are high or low, so that we can better uncover how food, exercise and medication affect their sugar levels. This provides me the opportunity to have more informed discussions and to customize the diabetes management plans for my patients, and augments the personal engagement of patients thereby motivating them to adhere to therapeutic advice.”
Yesterday, Medtronic announced a deal with Novo Nordisk to integrate insulin dosing data from Novo Nordisk’s smart insulin pens into Medtronic’s CGM devices.
Shares of MDT were up 0.4% to $109.46 per share in early-morning trading today.